Company Overview of MAP Pharmaceuticals, Inc.
MAP Pharmaceuticals, Inc., a development stage company, focuses on the enhancement of the therapeutic benefits and commercial attractiveness of proven drugs in the field of neurology through its formulation and inhalation technologies. The company’s lead product candidate includes LEVADEX, an orally inhaled version of dihydroergotamine mesylate (DHE) that has completed Phase III clinical trials for the acute treatment of migraine in adults. Its proprietary technologies consist of particle creation and formulation technologies, which can be applied to small or large molecules, including peptides and proteins; and aerosol delivery platforms, such as TEMPO inhaler, a pressurized metered dose in...
2400 Bayshore Parkway
Mountain View, CA 94043
Founded in 2003
Key Executives for MAP Pharmaceuticals, Inc.
Chief Executive Officer and President
Senior Vice President of Neurology Franchise
Compensation as of Fiscal Year 2014.
MAP Pharmaceuticals, Inc. Key Developments
MAP Pharmaceuticals, Inc.(NasdaqGS:MAPP) dropped from NASDAQ Biotechnology Index
Mar 4 13
MAP Pharmaceuticals, Inc. will be removed from NASDAQ Biotechnology Index.
MAP Pharmaceuticals, Inc.(NasdaqGS:MAPP) dropped from NASDAQ Composite Index
Mar 4 13
MAP Pharmaceuticals, Inc. will be removed from NASDAQ Composite Index.
MAP Pharmaceuticals, Inc. Announces Board Changes
Mar 1 13
On March 1, 2013, Thomas A. Armer, Gerri A. Henwood, Bernard J. Kelley, Matthew V. McPherron, Timothy S. Nelson, W. James O’Shea, Scott R.
Ward and H. Ward Wolff resigned as directors of MAP Pharmaceuticals, Inc. and David E.I. Pyott, Jeffrey L. Edwards and Arnold A. Pinkston became directors of MAP.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries